---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-105688"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-09-08T12:09:26+00:00"
generated_at: "2026-09-08T12:10:09.122373+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics: ACCG-2671 SAD positive, aleniglipron 72-wk OLE up to 16.2% weight loss

## Summary
- ACCG-2671 SAD: 31 healthy adults, ~6-day half-life, no SAEs, 3.3% mean weight loss at Day 24 (10 mg), CTX-1 down ~60%.
- Aleniglipron 72-wk OLE: 11.6%/14.4%/16.2% weight loss for 45/90/120 mg arms; >1/3 of 90/120 mg cohorts >20% loss (35.9/40.5 lbs).
- Placebo crossover with 2.5 mg start: 9.0% (22.7 lbs) at 36 wks; <5% discontinuation due to AEs; improved GI tolerability.
- Phase 3 ACCOMPLISH-1 (3,600) and -2 (1,100) enrolling; topline 2H 2028. ACCG-2671 MAD topline 1H 2027.
- Q4 2026 readouts: body composition, T2DM, and SWITCH trial results.

## SEC filing metadata
- accession: 0001104659-26-105688
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-09-08T12:09:26+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/0001104659-26-105688-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-105688
- JSON: https://secwatch.observer/filing/0001104659-26-105688.json
- Plain text: https://secwatch.observer/filing/0001104659-26-105688.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.